The quarter fell short on the two headline financial measures the market was watching. Total revenue of $7.7 million was about 37% below the published consensus of roughly $12.2 million, while the $0.25 per-share loss was slightly wider than the roughly $0.23 expected loss. The revenue decline was attributed to fewer Roche/Genentech project phases completing than in the prior-year quarter—not a stated loss of a partner—yet it reinforces how variable collaboration revenue remains. (Condensed Statements of Operations; Revenue discussion)
| Metric | Q2 2026 actual | Comparison | Read versus expectation |
|---|---|---|---|
| Total revenue | $7.7M | $19.2M in Q2 2025; published consensus ~$12.2M | Below consensus |
| Net loss per share | $(0.25) | $(0.41) in Q2 2025; published consensus ~$(0.23) | Slightly worse than expected |
| Net loss | $(131.0)M | $(171.9)M in Q2 2025 | Improved year over year |
| R&D expense | $89.6M | $128.6M in Q2 2025 | Lower, partly aided by lower non-cash Tempus data expense |
| H1 cash operating expense | $191.0M | $199.1M in H1 2025 | Lower year over year |
| Full-year cash operating expense guidance | $375M | Reduced by $15M from prior guidance | Constructive offset |
| Cash and equivalents | $545.7M | $743.3M at December 31, 2025 | Material cash drawdown remains |
The cost reset is the clearest offset, but it does not erase the revenue miss. Management cut full-year cash operating expense guidance by $15 million to $375 million, after H1 cash operating expense declined to $191 million from $199.1 million. That supports the efficiency story and helped narrow the accounting loss year over year. But quarterly operating cash use rose to $105.9 million from $76.4 million, even if the prior year benefited from a $28.6 million UK R&D tax-credit inflow; cash and equivalents still declined by about $198 million since year-end. (Cash Operating Expense reconciliation; Condensed Statements of Cash Flows; Condensed Balance Sheets)
The Genentech milestone is strategically credible but still early-stage rather than near-term revenue. Genentech exercised its first validated-target option in the neuroscience collaboration, moving a previously unexplored target into joint small-molecule discovery. That is a useful external validation of the platform—the partner is advancing an internally generated target—but the filing does not disclose a new payment tied to this option, and the program remains before clinical development. It improves the platform proof-point more than it changes near-term financial expectations. (Genentech neuroscience collaboration update)
Pipeline execution met the stated timetable without providing a new clinical-value inflection. REC-7735 cleared its IND and is set to enter Phase 1/2 in the second half of 2026, while additional REC-4881 Phase 2 data are scheduled for November. These are tangible advances, but they were schedule confirmations and future data commitments rather than new efficacy results in this filing. (Pipeline updates — REC-7735; Continued Momentum for REC-4881)
Net: the filing is weaker than expected financially, with lower spending guidance and partner validation limiting—but not reversing—the shortfall.
Read the original 8-K on SEC EDGAR ↗